Neovasc Inc (NVCN.CA) Stock Price, Forecast & Analysis
Canada - TSX:NVCN - CA64065J4037 - Common Stock
NVCN.CA Key Statistics, Chart & Performance
The current stock price of NVCN.CA is 40.15 CAD. In the past month the price decreased by -1.21%. In the past year, price increased by 203.02%.
NVCN.CA Latest News, Press Relases and Analysis
NVCN.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| PRN.CA | PROFOUND MEDICAL CORP | N/A | 272.59M | ||
| MIR.CA | MEDMIRA INC | N/A | 56.87M | ||
| TLT.CA | THERALASE TECHNOLOGIES INC | N/A | 50.79M | ||
| CNVI.CA | CONAVI MEDICAL CORP | N/A | 47.59M | ||
| PINK.CA | PERIMETER MEDICAL IMAGING AI | N/A | 27.32M | ||
| ASG.CA | AURORA SPINE CORP | N/A | 23.17M | ||
| NSCI.CA | NANALYSIS SCIENTIFIC CORP | N/A | 21.82M | ||
| MDX.CA | MEDX HEALTH CORP | N/A | 18.53M | ||
| VPT.CA | VENTRIPOINT DIAGNOSTICS LTD | N/A | 15.93M | ||
| THRM.CA | THERMA BRIGHT INC | N/A | 3.41M | ||
| VER-H.CA | VERISANTE TECHNOLOGY INC | N/A | 439.40K | ||
| VVTM.CA | VVT MED INC | N/A | 18.71M |
Related stock screener links
About NVCN.CA
Company Profile
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2001-05-23. The firm develops, manufactures, and markets products for the cardiovascular marketplace. The firm is engaged in the development of minimally invasive therapies in cardiovascular care: refractory angina and mitral valve regurgitation. Its products include the Neovasc Reducer (Reducer), for the treatment of refractory angina, and the Tiara (Tiara), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. The firm operates through one business segment: the development, manufacturing and marketing of medical devices. The firm's subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc. The firm carries its business in Canada, the United States and Europe.
Company Info
Neovasc Inc
Richmond, 5138-13562 Maycrest Way
Richmond British Columbia BRITISH COLUMBIA V6V 2J7 CA
CEO: Fredericus A. Colen
Employees: 71
Phone: 16042704344.0
Neovasc Inc / NVCN.CA FAQ
What does NVCN do?
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2001-05-23. The firm develops, manufactures, and markets products for the cardiovascular marketplace. The firm is engaged in the development of minimally invasive therapies in cardiovascular care: refractory angina and mitral valve regurgitation. Its products include the Neovasc Reducer (Reducer), for the treatment of refractory angina, and the Tiara (Tiara), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. The firm operates through one business segment: the development, manufacturing and marketing of medical devices. The firm's subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc. The firm carries its business in Canada, the United States and Europe.
What is the current price of NVCN stock?
The current stock price of NVCN.CA is 40.15 CAD. The price increased by 0.58% in the last trading session.
Does Neovasc Inc pay dividends?
NVCN.CA does not pay a dividend.
What is the ChartMill rating of Neovasc Inc stock?
NVCN.CA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for NVCN stock?
Neovasc Inc (NVCN.CA) currently has 71 employees.
NVCN.CA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NVCN.CA. When comparing the yearly performance of all stocks, NVCN.CA is one of the better performing stocks in the market, outperforming 98.96% of all stocks.
NVCN.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVCN.CA. Both the profitability and financial health of NVCN.CA have multiple concerns.
NVCN.CA Financial Highlights
Over the last trailing twelve months NVCN.CA reported a non-GAAP Earnings per Share(EPS) of -142.14. The EPS decreased by -1143.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.81 |